96 28

Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer

Title
Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer
Author
문홍상
Keywords
Chemokine CCL11; Prostatic hyperplasia; Prostatic neoplasms
Issue Date
2016-11
Publisher
대한요로생식기감염학회
Citation
Urogenital Tract Infection, v. 11, NO 3, Page. 103-108
Abstract
Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoattractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa. Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11. Results: CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men. Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.
URI
https://synapse.koreamed.org/DOIx.php?id=10.14777/uti.2016.11.3.103https://repository.hanyang.ac.kr/handle/20.500.11754/101103
ISSN
2465-8243; 2465-8510
DOI
https://doi.org/10.14777/uti.2016.11.3.103
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE